4.2 Article

Epigenetics and B-cell lymphoma

期刊

CURRENT OPINION IN HEMATOLOGY
卷 18, 期 4, 页码 293-299

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOH.0b013e32834788cf

关键词

chromatin modifications; DNA methylation; epigenetic programming; enhancer of zeste 2; histone acetyltransferase

资金

  1. Leukemia and Lymphoma Society [6304-11]
  2. NCI [R01 CA 104348]
  3. Chemotherapy Foundation
  4. Burroughs Wellcome Foundation
  5. [K08 CA127353]

向作者/读者索取更多资源

Purpose of review It has only recently become apparent that mutations in epigenetic mechanisms and perturbation of epigenomic patterning are frequent events in B-cell lymphomas. The purpose of this review is to highlight these new findings and provide a conceptual framework for understanding how epigenetic modifications might contribute to lymphomagenesis. Recent findings Somatic mutations affecting histone methyltransferases such as enhancer of zeste 2 and mixed lineage leukemia 2, histone demethylases including ubiquitously transcribed X chromosome tetratricopeptide repeat and Jumonji domain-containing 2C, and histone acetyltransferases including CBP and p300 are recurrent and common in lymphomas. These mutations result in disruption of chromatin structure and functions of other proteins, ultimately causing aberrant transcriptional programming affecting multiple gene networks. Widespread perturbation of cytosine methylation patterning now appears to be a hallmark of B-cell lymphomas and occurs in specific patterns that can distinguish disease subtypes. Therapeutic targeting strategies can overcome abnormal epigenetic mechanisms and potently kill lymphoma cells. Summary Newly discovered epigenetic lesions may provide critical insights into the genesis of B-cell lymphomas, but further studies are required to understand how they affect biological mechanism. Epigenetic lesions offer tremendous opportunities for the development of improved biomarkers and treatments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据